Precision Medicine in NSCLC: Ramifications of Recent Data

Precision Medicine in NSCLC: Ramifications of Recent Data

Episodes

Specialty:

All

Year:

All

EP. 1: Molecular Testing for NSCLC in 2019

July 19th 2019

EP. 2: Acting on Molecular Testing Results in NSCLC

July 19th 2019

EP. 3: Molecular Testing for Patients With Symptomatic NSCLC

July 19th 2019

EP. 4: How Are We Using Liquid Biopsy in NSCLC?

July 19th 2019

EP. 5: EGFR-Mutated NSCLC; Where We Are Now?

July 19th 2019

EP. 6: Treating EGFR+ NSCLC Brain Metastases

July 19th 2019

EP. 7: Novel EGFR Inhibitor Combinations for NSCLC

July 19th 2019

EP. 8: RELAY: Erlotinib with Ramucirumab for EGFR+ NSCLC

July 19th 2019

EP. 9: Novel EGFR Exon 20 Directed Therapies for NSCLC

July 19th 2019

EP. 10: ALK-Rearranged Lung Cancer

July 19th 2019

EP. 11: Managing CNS Disease in ALK-Rearranged NSCLC

July 19th 2019

EP. 12: ROS1-Rearranged NSCLC

July 19th 2019

EP. 13: Treatment of NSCLC Rare Genotypes

July 19th 2019

EP. 14: The NTRK Family of Fusions in NSCLC

July 19th 2019

EP. 15: Treatment of NSCLC With RET Fusions

July 19th 2019

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma